Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (TEM) is a pioneering technology company dedicated to revolutionizing healthcare through its innovative AI-driven solutions. The company has developed the Tempus Platform, a sophisticated technology framework designed to liberate healthcare data from restrictive silos and transform it into actionable insights. This platform is complemented by a robust operating system that ensures the resulting data is not only accessible but also incredibly useful for healthcare providers.
One of Tempus AI's standout features is its Intelligent Diagnostics suite, which leverages advanced AI, including generative AI, to enhance the accuracy, personalization, and effectiveness of laboratory tests. This cutting-edge technology enables more precise diagnostic results, leading to better patient outcomes and more efficient healthcare processes.
The company is continuously working on innovative projects and forging strategic partnerships to expand its impact in the healthcare sector. Recent achievements include significant advancements in AI algorithms and successful integrations with major healthcare systems, further cementing its position as a leader in the field.
Financially, Tempus AI has shown robust growth and maintained a solid economic foundation, attracting the interest of investors and stakeholders alike. The company's performance is closely monitored by analysts, particularly due to its potential to disrupt the healthcare landscape with its state-of-the-art technological solutions.
For investors seeking the latest updates and detailed information about Tempus AI's performance, events, and developments, staying informed through reliable sources is crucial. The company's ongoing projects and recent news reflect its commitment to innovation and excellence in the healthcare technology arena.
Tempus reported Q3 2024 financial results and announced the acquisition of Ambry Genetics for $600M ($375M cash, $225M shares). Revenue grew 33% YoY to $180.9M, with data services revenue up 64.4% and genomics unit growth of 23.9%. The company posted a net loss of $(75.8M), including $22.2M in stock compensation. Ambry Genetics is expected to generate >$300M revenue and >$40M EBITDA in 2024. The acquisition expands Tempus' testing capabilities in hereditary cancer screening and new disease categories. Full-year 2024 guidance maintains at ~$700M revenue.
Tempus AI (NASDAQ: TEM) announced it will report its third quarter 2024 financial results on Monday, November 4, 2024. The earnings conference call is scheduled for 4:30 p.m. ET on the same day, replacing the previously scheduled November 7 call. CEO Eric Lefkofsky and CFO Jim Rogers will lead the call, which will be accessible via webcast through Tempus' Investor Relations website or by phone using provided dial-in numbers.
Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024. The earnings conference call will be held at 4:30 p.m. ET, featuring CEO Eric Lefkofsky and CFO Jim Rogers. The call will be accessible through Tempus' Investor Relations website's events page, with both domestic and international dial-in options available.
Tempus AI, Inc. (NASDAQ: TEM) announces an expanded collaboration with Takeda to enhance oncology research and development. The partnership leverages Tempus' de-identified multimodal datasets and biological modeling capabilities to advance Takeda's cancer therapeutics pipeline. Takeda researchers will use Tempus' analytics platform, Lens, to access de-identified patient records and AI-enabled tools.
The collaboration includes a multi-phase biological modeling project using one of the world's largest repositories of patient-derived tumor organoids. Tempus is working with Takeda on a panel of 60 organoids spanning 10 cancer indications to evaluate preclinical candidates. This approach aims to enhance drug effectiveness prediction and guide early candidate prioritization.
Initial work has already yielded research to be presented at an upcoming medical congress, demonstrating the potential of this data-first approach in accelerating insights for drug development.
Tempus AI (NASDAQ: TEM) announced four abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The presentations include:
1. An oral presentation on the impact of AI in clinical trial screening and enrollment.
2. A poster on using circulating tumor DNA (ctDNA) to monitor treatment response in patients treated with tyrosine kinase inhibitors.
3. A poster on comprehensive genomic profiling for targeted therapy in advanced lung cancer patients.
4. A poster on the impact of RAS and BRAFV600E mutations on the tumor immune microenvironment in colorectal cancers.
These presentations showcase Tempus' commitment to leveraging AI and data to advance precision medicine and improve patient outcomes in oncology.
Tempus AI, Inc. (NASDAQ: TEM) has launched the beta version of olivia, an AI-enabled personal health concierge app for patients. This innovative app aims to empower individuals to manage their health data holistically. olivia uses generative AI to provide personalized support, offering features such as:
- Seamless connection with healthcare providers
- Comprehensive patient profile creation
- Appointment preparation assistance
- Health monitoring tools
The app addresses the challenge of managing healthcare data across multiple providers and specialties, offering users a centralized platform to organize and access their health information. Tempus CEO Eric Lefkofsky emphasized that olivia leverages the company's investments in AI and multimodal healthcare data aggregation to benefit patients directly.
Tempus AI (NASDAQ: TEM) has announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX) to enhance BioNTech's next-generation oncology pipeline. The partnership leverages Tempus' large multimodal datasets and computational biology expertise to support BioNTech's research and development efforts in oncology.
Tempus will provide analytical support and access to its real-world multimodal database to help BioNTech generate novel insights into biological mechanisms. This collaboration aims to advance the discovery of new therapies and enhance the development of BioNTech's clinical oncology pipeline. The partnership combines Tempus' real-world data and computational technology with BioNTech's AI capabilities and multi-platform discovery engine to potentially bring innovative therapies to cancer patients.
Tempus AI (NASDAQ: TEM), a leader in AI-driven precision medicine, is set to participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024, in New York. The company's Founder and CEO, Eric Lefkofsky, will engage in a fireside discussion at 8:30 a.m. ET during the event.
This participation highlights Tempus' commitment to advancing healthcare through technology and AI. The conference provides a platform for Tempus to showcase its innovations and discuss the future of precision medicine with industry leaders and investors.
BerGenBio ASA (OSE: BGBIO) reported solid clinical and financial progress in its Q2 2024 results. Key highlights include:
1. BGBC016 1L NSCLC STK11m study progressing well, with Ph1b enrollment completed and Ph2a sites activated.
2. Collaboration with Tempus AI (Nasdaq: TEM) to accelerate bemcentinib development using genomic AI.
3. Strengthened financial position with NOK 138.9 million from warrant exercise, funding secured into H2 2025.
4. Stable cash use with decreased operating expenses: NOK 90.5 million for H1 2024 vs NOK 120.2 million in H1 2023.
5. Focus on bemcentinib as a potential first-in-class selective AXL inhibitor for STK11 mutated NSCLC and severe respiratory infections.
Personalis (PSNL) and Tempus (TEM) have expanded their commercial collaboration, with Tempus investing $36 million in Personalis. This investment includes exercising warrants to purchase 9.2 million shares at an average price of $2.00 and buying an additional 3.5 million shares at $5.07 each. The expansion follows strong demand for their ultra-sensitive MRD testing in breast and lung cancers, as well as immunotherapy monitoring across solid tumors.
Key points of the expanded collaboration include:
- Tempus accelerating commercialization efforts over the first two years
- Personalis increasing the quantity of patient samples it will accept
- Tempus becoming the exclusive commercial partner for Personalis' MRD product
- Tempus owning approximately 19.3% of Personalis' outstanding common stock after the transaction
FAQ
What is the current stock price of Tempus AI (TEM)?
What is the market cap of Tempus AI (TEM)?
What is Tempus AI, Inc.?
What does the Tempus Platform do?
How does Tempus AI use AI in healthcare?
What are Intelligent Diagnostics?
What are some recent achievements of Tempus AI?
How is Tempus AI financially performing?
Who are Tempus AI's partners?
Why is Tempus AI significant in the healthcare sector?
What is the importance of the operating system in the Tempus Platform?
How can I stay updated on Tempus AI's latest news?
